GLP-1 + Cagrilintide

$216.00

Quantity

5mg

10mg

Purity Grade

99%

Quantity

Typical Dosing Protocols (Research/Compounded Use Only) Dosing Protocols (Research/Investigational)

+ Semaglutide (fixed-dose combination known as CagriSema) is Novo Nordisk’s once-weekly injectable dual agonist. It combines:

Semaglutide (2.4 mg) — a GLP-1 receptor agonist (the active ingredient in Wegovy and Ozempic) that reduces appetite, slows gastric emptying, and improves glycemic control.
Cagrilintide (2.4 mg) — a long-acting amylin receptor agonist (an analog of the pancreatic hormone amylin) that enhances satiety, further slows gastric emptying, and complements GLP-1 action.

The two mechanisms are synergistic: GLP-1 primarily curbs hunger and improves glucose regulation, while amylin adds stronger feelings of fullness and helps regulate post-meal glucose spikes.

Current Status (as of April 2026)

CagriSema is not yet FDA-approved in the United States (or most Western countries). Novo Nordisk submitted a New Drug Application for weight management in December 2025 based on the REDEFINE program, with an expected FDA decision in late 2026.
It is further along in development for both obesity and type 2 diabetes.

Key Efficacy Data from Phase 3 Trials

REDEFINE 1 (obesity/overweight without diabetes, 68 weeks):
- Mean weight loss: 20.4% (up to 22.7% with full treatment adherence).
- Superior to semaglutide 2.4 mg alone (14.9%) and cagrilintide alone (11.5%).
- ~40% of participants achieved ≥25% weight loss in some analyses.
REIMAGINE 2 (type 2 diabetes, 68 weeks):
- Weight loss: 14.2% with CagriSema vs 10.2% with semaglutide 2.4 mg.
- Superior HbA1c reduction: -1.91% vs -1.76% with semaglutide.
REDEFINE 4 (head-to-head vs tirzepatide 15 mg in obesity, 84 weeks):
- CagriSema achieved 23% mean weight loss (full adherence) or 20.2% (treatment-regimen estimand).
- Tirzepatide achieved 25.5% (full adherence) or 23.6% (treatment-regimen).
- Did not meet the primary endpoint of non-inferiority to tirzepatide.
No clear weight-loss plateau was observed at the end of many trials, suggesting potential for further loss with longer treatment.

CagriSema consistently outperforms semaglutide alone (by ~5–8 percentage points in weight loss) and shows additive benefits from the amylin component.

Cardiometabolic and Other Benefits

Reductions in waist circumference, blood pressure, lipids, and liver fat.
Improved insulin sensitivity and glycemic control (especially relevant in type 2 diabetes).
High responder rates: Many participants achieve clinically meaningful thresholds (≥15%, ≥20%, or ≥25% weight loss).

Key Potential Benefits of Cagrilintide + Semaglutide (CagriSema)
Superior Weight Loss (Potentially Among the Strongest Non-Surgical Options)
In REDEFINE 1 (adults with overweight/obesity without diabetes): Mean body weight reduction of 20.4% (treatment policy) to 22.7% (if all adhered to treatment) at 68 weeks, with continued loss and no clear plateau in many participants; 40–53% achieved ≥20% weight loss and up to 34.7% achieved ≥25%.
In REDEFINE 2 (adults with overweight/obesity and type 2 diabetes): Mean weight loss of 13.7–15.7% at 68 weeks.
In REIMAGINE 2 (type 2 diabetes): 14.2% weight loss vs 10.2% with semaglutide 2.4 mg alone at 68 weeks.
Outperforms monotherapy: Superior to semaglutide alone (by ~5.5%) and cagrilintide alone (by ~8.9%) in head-to-head comparisons, approaching or rivaling outcomes seen with more invasive interventions in select data.
Enhanced Satiety, Appetite Control, and Reduced Food Intake
Cagrilintide activates amylin receptors in the brainstem and hypothalamus to promote profound feelings of fullness, reduce hunger signals, and blunt the rewarding aspects of food.
Semaglutide provides strong GLP-1-mediated appetite suppression, delayed gastric emptying, and reduced cravings.
Together: Complementary multi-pathway reinforcement (GLP-1 + amylin) leads to more robust and sustained satiety, improved adherence, and fewer compensatory hunger episodes compared to either agent alone.
Improved Glycemic Control and Type 2 Diabetes Management
Significant HbA1c reductions: Up to 1.91 percentage points in REIMAGINE 2 (superior to 1.76 points with semaglutide alone); ~1.8–2.2 points in earlier trials.
High rates of target achievement: 73.5% reaching HbA1c ≤6.5% and up to 89% reaching <7.0% in some studies.
Enhances insulin sensitivity, suppresses postprandial glucagon, and supports better overall glucose regulation, with potential for prediabetes reversal or normoglycemia in a large proportion of participants.
Favorable Cardiometabolic and Body Composition Improvements
Reductions in waist circumference (up to –13.4 cm), systolic blood pressure (–6.7 to –10.9 mmHg), and inflammatory markers (e.g., high-sensitivity C-reactive protein).
Improvements in lipid profiles, liver fat, and other metabolic parameters beyond what weight loss alone explains in some analyses.
Supports better physical function scores (e.g., IWQOL-Lite-CT and SF-36) and overall quality of life related to mobility and daily activities.
Synergistic Advantages Over Monotherapy
Dual targeting of complementary hunger/satiety pathways (GLP-1 for central and gut effects + amylin for brainstem reinforcement) creates broader appetite regulation and potentially delays or reduces weight loss plateaus.
Additive effects on energy balance, gastric motility, and metabolic signaling lead to greater total weight reduction and metabolic benefits than semaglutide or cagrilintide used individually.
Maintains a profile consistent with the GLP-1 class while delivering meaningful incremental efficacy through amylin co-activation.

GLP-1 + Cagrilintide

Current Status (as of April 2026)

Key Efficacy Data from Phase 3 Trials

Cardiometabolic and Other Benefits

Cagrilintide + Semaglutide

Key Potential Benefits of Cagrilintide + Semaglutide (CagriSema)

Research

HQ

Social